Abstract
Purpose of Review
Primary ovarian insufficiency (POI), a clinical syndrome, is defined by the exhaustion of the functional potential of ovaries prior to 40 years. The consequences of POI are potentially serious for long-term fertility, reproductive health, and general health because of early menopause. This article provides an updated review of different etiologic factors and pathogenic mechanisms that lie behind POI as well as current and novel strategies for the management of this challenging disease aimed at the primary prevention of the adverse effects of estrogen deficiency and infertility related to the early loss of ovarian function.
Recent Findings
POI is considered as a multifactorial and heterogeneous condition with a wide spectrum of causes, such as cytogenetic, autoimmune, infectious, metabolic, or iatrogenic causes. Most women affected with isolated POI still appear sporadically, and the exact underlying pathology remains unknown. For early prediction of the risk of POI and prevention of the detrimental consequences of POI in terms of fecundity and general health, the determination of characteristics and the risk assessment of the POI population may be more important than the prediction of the prevalence of POI in the general population.
Summary
POI has widespread consequences for general health and fertility. Challenges remain in the modalities of assessment and management of this complex condition. This review primarily focuses on the key questions and recommendations for clinical practice regarding the assessment and management of women diagnosed with POI. Therefore, this article provides an updated review of novel findings regarding the diagnosis and management of this challenging disease.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Alvaro Mercadal B, Imbert R, Demeestere I, Gervy C, De Leener A, Englert Y, Costagliola S, Delbaere A. AMH mutations with reduced in vitro bioactivity are related to premature ovarian insufficiency. Hum Reprod. 2015;30(5):1196–202.
Albright F, Smith P, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature. Am J Med Sci. 1942;204:625–48.
De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;11:376(9744):911–21.
Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360:606–14.
Bachelot A, Rouxel A, Massin N, Dulon J, Courtillot C, Matuchansky C, Badachi Y, Fortin A, Paniel B, Lecuru F, Lefrère-Belda MA, Constancis E, Thibault E, Meduri G, Guiochon-Mantel A, Misrahi M, Kuttenn F. Touraine P; POF-GIS study group phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol. 2009;161(1):179–87.
Voorhuis M, Onland-Moret NC, van der Schouw YT, Fauser BCJM, Broekmans FJ. Human studies on genetics of the age at natural menopause: a systematic review. Hum Reprod Update. 2010;16:364–77.
Broekmans FJ, Soules MR. Fauser BC ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009;30(5):465–93.
Anasti J. Premature ovarian failure: an update. Fertil Steril. 1998;70:1–15.
Richardson MC, Guo M, Fauser BC, Macklon NS. Environmental and developmental origins of ovarian reserve. Hum Reprod Update. 2014;20(3):353–69.
Daan NM, Hoek A, Corpeleijn E, Eijkemans MJ, Broekmans FJ, Fauser BC, Koster MP. Reproductive characteristics of women diagnosed with premature ovarian insufficiency. Reprod BioMed Online. 2016;32(2):225–32.
• Haller-Kikkatalo K, Uibo R, Kurg A, Salumets A. The prevalence and phenotypic characteristics of spontaneous premature ovarian failure: a general population registry-based study. Hum Reprod. 2015;30(5):1229–38. They include the most updated information related to prevalence, characteristics
•• Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck K-SS, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. European Society for Human Reproduction and Embryology (ESHRE) guideline group on POI. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–37. They include the most updated guideline by ESHRE related to the management of women with POI
•• Qin Y, Xue J, Simpson JL, Che Z-J. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update. 2015;21:787–808. They include the most updated information related to new developments for POI
Vichinsartvichai P. Primary ovarian insufficiency associated with autosomal abnormalities: from chromosome to genome-wide and beyond. Menopause. 2016;23(7):806–15.
Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, Rebar RW, Corrigan EC, Simpson JL, Nelson LM. The FMR1 premutation and reproduction. Fertil Steril. 2007;3:456–65.
Simpson JL. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann N Y Acad Sci. 2008;1135:146–54.
van Dooren M, Bertoli-Avellab A, Oldenburg R. Premature ovarian failure and gene polymorphisms. Curr Opin Obstet Gynecol. 2009;21:313–7.
Aboura A, Dupas C, Tachdjian G, et al. Array comparative genomic hybridization profiling analysis reveals deoxyribonucleic acid copy number variations associated with premature ovarian failure. J Clin Endocrinol Metab. 2009;94:4540–6.
Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update. 2008;14:359–66.
Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015;18(4):483–91.
Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Women's Health. 2014;6:235–43.
•• Sassarini J, Lumsden MA, Critchley HO. Sex hormone replacement in ovarian failure–new treatment concepts. Best Pract Res Clin Endocrinol Metab. 2015;29(1):105–14. They include one of the most updated concept for hormone replacement treatment of POI
Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. Collaborators of the Dutch multidisciplinary guideline development group on cardiovascular risk management after reproductive disorders cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(2):178–86.
Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric. 2016;19(1):27–36.
Schnatz PF. The 2010 North American Menopause Society position statement: updates on screening, prevention and management of postmenopausal osteoporosis. Conn Med. 2011;75(8):485–7.
Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010–8.
Bidet M, Bachelot A, Bissauge EE, Golmard JL, Gricout S, Dulon J, Coussieu C, Badachi Y, Touraine P. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinl Metab. 2011;96:3864–72.
Donnez J, Dolmans MM. Fertility preservation in women. Nat Rev Endocrinol. 2013;9(12):735–49.
Robles A, Checa MA, Prat M, Carreras R. Medical alternatives to oocyte donation in women with premature ovarian failure: a systematic review. Gyn Endocrinol. 2013;29:632–7.
Kawamura K, Cheng Y, Sun YP, Zhai J, Diaz-Garcia C, Simon C, Pellicer A, Hsueh AJ. Ovary transplantation: to activate or not to activate. Hum Reprod. 2015;30(11):2457–60.
•• Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016;28(3):217–22. They include the most updated information related to new developments, opportunities, management (12-ESHRE guideline; 22-HRT) and new treatment concepts for POI
StoopD BM, Haentjens P, Polyzos NP, DeVos M, Verheyen G, Camus M, Devroey P. Obstetric outcome in donor oocyte pregnancies: a matched-pair analysis. Reprod Biol Endocrinol. 2012;10:42.
Naredi N, Sandeep K, Jamwal VDS. Can hormone replacement therapy prior to oocyte donation cycle in women with premature ovarian failure improve pregnancy rate? Med J Armed Forces India. 2013;69:357–60.
Podfigurna Stopa A, Czyzyk A, Grymowicz M, Smolarczyk R, Katulski K, Czajkowski K, Meczekalski B. Premature ovarian insufficiency: the context of long-term effects. J Endocrinol Investig. 2016;39:983–90.
Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, Morimoto Y, Kawamura K. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod. 2015;30:608–15.
•• VanderVen H, Liebenthron J, Beckmann M, Toth B, Korell M, Krus sel J, Frambach T, Kupka M, Hohl MK, Winkler-Crepaz K, Seitz S, Dogan A, Griesinger G, Haberlin F, Henes M, Schwab R, Sutterlin S, von Wolff M, Dittrich R. On behalf of the Ferti PROTEKT network ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment infertility preservation network: tissue activity, pregnancy and delivery rates. Hum Reprod. 2016;31:2031–41. They include the most updated information related to new developments, opportunities, management (12-ESHRE guideline; 22-HRT) and new treatment concepts for POI
Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32:1167–70.
• Chapman C, Cree L, Shelling AN. The genetics of premature ovarian failure: current perspectives. Int J Womens Health. 2015;23(7):799–810. They include the most updated information related to prevalence, characteristics and genetics of POI
Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):9–17.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Pınar Özcan, Parveen Parasar, and Cem Fıçıcıoğlu declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Reproductive Endocrinology and Infertility (REI)
The original version of this article was revised: The name of author Parveen Parvasar was changed to Parveen Parasar as requested by authors.
An erratum to this article is available at http://dx.doi.org/10.1007/s13669-017-0199-x.
Rights and permissions
About this article
Cite this article
Özcan, P., Parasar, P. & Fıçıcıoğlu, C. What Does the Data Show for Primary Ovarian Insufficiency?. Curr Obstet Gynecol Rep 6, 26–32 (2017). https://doi.org/10.1007/s13669-017-0191-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13669-017-0191-5